Gonadorelin vs Kisspeptin-54

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Full-length kisspeptin (54 amino acids); binds KISS1R on GnRH neurons with higher receptor occupancy and longer duration than KP-10; induces more sustained GnRH/LH pulses

Kisspeptin-54 (Kp-54) is the primary full-length endogenous form of the KISS1-derived peptide family, a hypothalamic neuropeptide that acts as the central regulator of GnRH pulsatility and reproductive hormone signaling. As a KISS1R agonist, kisspeptin-54 directly stimulates GnRH neurons, initiating LH and FSH release from the pituitary and driving downstream gonadal steroidogenesis in both males and females. Published research documents kisspeptin-54 regulation of the reproductive axis across the menstrual cycle and its emerging potential as a treatment for sexual dysfunction, with studies suggesting effects on reproductive hormone output and libido-related pathways. Kisspeptin-54 is an investigational compound; it is not approved by the FDA for any clinical indication and its applications in sexual health and fertility remain under active investigation. Kisspeptin-54 vs kisspeptin-10: length and activity distinctions Kisspeptin-54 (Kp-54) is the full-length 54-amino-acid endogenous KISS1-derived peptide, while kisspeptin-10 (Kp-10) is the C-terminal decapeptide fragment responsible for KISS1R (GPR54) binding activity. Both isoforms activate the same receptor, but Kp-54 has a longer plasma half-life and sustained GnRH-stimulating activity relative to the shorter fragment, making it the preferred form for clinical research contexts where prolonged hormonal response is required. In research settings, Kp-10's lower cost and simpler synthesis has led to its wider use in mechanistic studies, while Kp-54 is preferred in clinical trials involving ovulation induction. Kisspeptin-54 in IVF: A published phase 2 clinical trial (Abbara et al., NEJM 2020) demonstrated that kisspeptin-54 could serve as an ovulation trigger in IVF — replacing the conventional hCG trigger in women at high risk of ovarian hyperstimulation syndrome (OHSS). The kisspeptin-54 trigger produced lower OHSS rates compared to hCG while maintaining acceptable oocyte yields, establishing it as a clinically relevant alternative trigger agent for high-risk patients. This application positions kisspeptin-54 within fertility medicine as a potential hCG substitute rather than just a mechanistic research tool. It remains investigational outside of trial contexts and is not currently approved by the FDA or EMA for ovulation induction.